Skip Navigation
Department of Health and Human Services www.hhs.gov
 
This website is iPhone friendly.

This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.

A Case Study in Prostate Cancer Treatment: Utilizing Comparative Effectiveness Research for Patient-Centered Decisionmaking

To Receive a Certificate for This Activity:

Course Image
  1. 1. Read the Program Overview on this page.
  2. 2. Review the Faculty Biographies, Accreditation Statements, and Disclosure tabs.
  3. 3. Access the Activity in full.
  4. 4. Complete the Post-Test & Evaluation.
  5. 5. A printable certificate will be available immediately following the activity.

Program Overview

Activity Description

The Agency for Healthcare Research and Quality (AHRQ) published a systematic research review on the comparative risks and benefits of therapies for clinically localized prostate cancer. In selected analyses, outcomes were stratified by tumor characteristics, patient demographics, and provider/hospital qualities. How can practitioners utilize the findings in their discussions with patients about treatment and management options? This case-based video illustrates effective methods for utilizing the evidence with a goal to achieve patient-centered decisionmaking. Treatment options discussed for clinically localized prostate cancer include watchful waiting (active surveillance), radical prostatectomy, external beam radiotherapy, brachytherapy, and androgen deprivation therapy.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Assess the efficacy and safety of treatment options for preventing biochemical progression, inhibiting metastasis, and prolonging survival in clinically localized prostate cancer
  • Apply the findings pertaining to influences of patient, tumor, and provider/hospital characteristics to discuss potential treatment outcomes with patients
  • Identify effective communication strategies for patient education through video case-based learning

Target Audience

This CME activity is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, pharmacists, nurses, case managers, health education specialists, and medical assistants.

Method of Participation

To receive a certificate for this activity, you should:

  • Complete the learner assessment pretest
  • View the entire activity online
  • Complete an online evaluation & post-test
  • Print your certificate online

The estimated time to complete this activity, including review of the materials, is 1.0 hour.

Term of Approval

August 31, 2012 through August 30, 2014. Original release date: August 31, 2012.

Acknowledgement of Support

There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).

Faculty Biographies and Disclosures

Click faculty name to view full biography.

Speaker

Peter C Albertsen, MD, MS
Professor
Division Chief and Residency Program Director
Associate Dean for Clinical Research Planning & Administration
University of Connecticut Health Center
Division of Urology
Farmington, Connecticut

Planner

Carolyn LePage, PhD, ARNP
Assistant Professor
Barry University School of Nursing
Miami Shores, FL

Planner

Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Adjunct Faculty
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Washington, DC

Planner

Michele B Kaufman, PharmD, CGP, RPh
President, PRN Communications Inc.
Editor, Pharmacovigilance Forum, P&T Journal
NYCSHP Secretary
Adjunct Faculty
Touro College of Pharmacy
New York, NY

Planner

Wanda F Carter, MPH, CHES
Adjunct Professor, Kaplan University Master of Public Health Program
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, LA College International Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office

Peer Reviewer

Michael N Baxley, MD, MS, MPH
Chief of Quality Medical Initiative
MCCI Medical Group
Miami, FL
President and Founder Physician
AUK DOK
Managed Care Consulting Service Company
Miami, FL

Peer Reviewer

Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
Adjunct Faculty & Preceptor
Albany College of Pharmacy
Albany, NY

Peer Reviewer

Joyce M Knestrick, PhD, CRNP, FAANP
Coordinator of Graduate Education
Frontier School of Midwifery and Family Nursing
Certified Family Nurse Practitioner
The Primary Care Center
Mt Morris, PA

Peer Reviewer

Kathleen A Jarvis, MS, RN, CCM
Clinical Educator
Alere Healthcare
Fort Lauderdale, FL

Begin Activity

Accreditation/Credit Designation

Physician Credit Designation Statement

A C C M E Logo

PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PRIME® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.

Nurse Practitioner Accreditation Statement

Nurse Practitioner Logo

PRIME Education, Inc (PRIME®) is approved as a provider of Nurse Practitioner Continuing Education by the American Association of Nurse Practitioners. Provider number: 060815. This program is accredited for 1.0 contact hour. Program ID# CER44.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Pharmacist Accreditation StatementA C P E Logo

PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME®. The Universal Activity Number for this program is 0255-0000-12-036-H01-P. This learning activity is Knowledge-Based.

Nurse Accreditation StatementA N C C Logo

PRIME Education, Inc. (PRIME®) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

PRIME® designates this activity for 1.0 contact hour.

Certified Health Education Specialist Accreditation Statement

Sponsored by PRIME Education, Inc. (PRIME®), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.

This program is designated for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I contact hours in health education.

CHES Provider Number: MEP3774

Begin Activity

Faculty Disclosures

Faculty Name
Advisory Board Consultant Grants / Research Salary / Contractual Supported Promotional Education Stock / Shareholder Other Financial Support
Peter C Albertsen, MD, MS
Speaker
Blue Cross Blue Shield None None National Cancer Institute None None None
Carolyn LePage, PhD, ARNP
Planner
None None None Barry University None None None
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
Planner
Sanofi-Aventis None None None None None None
Michele B Kaufman, PharmD, CGP, RPh
Planner
None OrthoMcNeil Janssen None None None None None
Wanda F Carter, MPH, CHES
Planner
None None None None None None None
Michael N Baxley, MD, MS, MPH
Reviewer
None None None None None None None
Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
Reviewer
None None None None None None None
Joyce M Knestrick, PhD, CRNP, FAANP
Reviewer
None None None None None None None
Kathleen A Jarvis, MS, RN, CCM
Reviewer
None None None None None None None
Chris R Prostko, PhD
Scientific Program Director
NoneNoneNonePRIME®NoneNoneNone
Lynn Goldenberg, RN, BSN
Director of Accreditation & Compliance
NoneNoneNonePRIME®NoneNoneNone

Disclosure Policy

PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.

Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.

Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.

Accessibility

PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.

Begin Activity

Pretest

To access the activity, please complete this brief Pretest.

  • Returning user? Login Here!
  1. Before accessing this educational activity, were you aware of the AHRQ-supported comparative effectiveness research on localized prostate cancer treatments?

  2. In AHRQ’s systematic review on treatments for clinically localized prostate cancer, radical prostatectomy was more effective than watchful waiting for reducing ________.

  3. Which of the following prostate cancer treatments are associated with urinary, bowel, and sexual dysfunction?

  4. How would you describe your current level of confidence in applying comparative effectiveness research on localized prostate cancer treatments?

  5. How valuable is comparative effectiveness research on localized prostate cancer treatments in making patient-centered treatment and management decisions?

  6. If you had a clinician summary/consumer summary on localized prostate cancer treatments, what would you most likely do?

  7. An otherwise healthy and active 70-year old male is diagnosed with localized high-risk prostate cancer (PSA > 20 ng/mL, Gleason grade ≥ 8, stage T2c). After counseling, the patient opts for curative treatment and not active surveillance (watchful waiting). Which of the following statements from the AHRQ review is true about curative treatments for localized prostate cancer and should be taken into consideration regarding this patient’s case? (check all that apply)

Post-Test & Evaluation

You must access the activity before receiving credit!

Clinician & Consumer Summaries on Prostate Cancer

Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.

AHRQ Clearinghouse Bulk Order Form

Returning user? Login Here
  • (Limit 200)
  • (This answer helps stop spam )
  • Alternatively, you can call the AHRQ Publications Clearinghouse at 1-800-358-9295. Reference the title and product number above.